Related Experiment Video

Updated: Aug 11, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Mechanisms of action: aspirin

J C Hoak

    Thrombosis Research. Supplement
    |January 1, 1983
    PubMed

    Insights

    Aspirin irreversibly inhibits platelet cyclo-oxygenase for antithrombotic therapy. However, endothelial cyclo-oxygenase can recover, and other NSAIDs may interfere with aspirin

    Area of Science:

    • Pharmacology
    • Biochemistry

    Background:

    • Aspirin is a long-established antiplatelet agent for antithrombotic therapy.
    • It inhibits cyclo-oxygenase and thromboxane synthesis in platelets irreversibly.

    Purpose of the Study:

    • To elucidate the mechanisms of aspirin's antiplatelet and antithrombotic effects.
    • To compare aspirin's action on platelet versus endothelial cyclo-oxygenase.
    • To investigate the interaction of other non-steroidal anti-inflammatory drugs (NSAIDs) with aspirin's action.

    Main Methods:

    • The study focuses on the biochemical mechanisms of cyclo-oxygenase inhibition by aspirin and other NSAIDs.
    • It examines the differential effects on platelets and endothelial cells.
    • Investigates the reversibility of enzyme inhibition and potential for recovery.

    Main Results:

    • Aspirin causes irreversible inhibition of platelet cyclo-oxygenase, lasting for the platelet's lifespan.
    • Endothelial cyclo-oxygenase is less sensitive to aspirin and can regenerate activity after drug removal.
    • Other NSAIDs, like ibuprofen, interact reversibly and may antagonize aspirin's effects.

    Conclusions:

    • Aspirin's irreversible platelet inhibition is key to its antithrombotic effect.
    • Differential sensitivity and recovery of endothelial cyclo-oxygenase are important considerations.
    • Concurrent use of certain NSAIDs may reduce aspirin's efficacy.

    More Related Videos

    Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea07:36

    Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

    Published on: December 23, 2022

    Related Concept Videos

    Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

    Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

    Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
    Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
    Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

    Indirect-Acting Cholinergic Agonists: Mechanism of Action

    Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
    Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Antiasthma Drugs: Methylxanthines01:24

    Antiasthma Drugs: Methylxanthines

    Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
    Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
    Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

    Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

    Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

    The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
    Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...